Alexandria Venture Investments, LLC
CIK 1722024 · last filed 2023-10-16
Alexandria Venture Investments, LLC is a corporate insider who has filed 34 SEC Form 4 insider transactions across 18 companies since 2017. Across all open-market trades the lifetime net is +$31.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $95.8M across reported positions. The firm reports its address in Pasadena, CA. 13 SEC filings were submitted jointly with ALEXANDRIA REAL ESTATE EQUITIES, INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$95.83M
18
34
$31.73M
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
PASADENA, CA 91101
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Applied Therapeutics, Inc. (APLT) Delisted | 10%+ Owner | 778,977 | $0.10 | $80.2K | $29.25M | 3 | 2023-10-16 |
| Vigil Neuroscience, Inc. (VIGL) Delisted | 10%+ Owner | 192,973 | $8.05 | $1.55M | $0 | 1 | 2022-01-11 |
| XLO | 10%+ Owner | 166,423 | $8.94 | $1.49M | $0 | 1 | 2021-10-26 |
| Singular Genomics Systems, Inc. (OMIC) Delisted | 10%+ Owner | 2,645,985 | $20.01 | $52.95M | $0 | 1 | 2021-06-01 |
| VOR | 10%+ Owner | 282,804 | $18.30 | $5.17M | $0 | 1 | 2021-02-09 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | 10%+ Owner | 699,412 | $5.87 | $4.11M | $0 | 1 | 2020-12-08 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 1,268,795 | $0.49 | $627.9K | $500.0K | 1 | 2020-09-18 |
| KYMR | 10%+ Owner | 467,932 | $110.91 | $51.90M | $0 | 1 | 2020-08-25 |
| RLAY | 10%+ Owner | 968,365 | $18.18 | $17.60M | $0 | 1 | 2020-07-20 |
| RNA | 10%+ Owner | 502,365 | $8.45 | $4.24M | $0 | 1 | 2020-06-16 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 293,013 | $14.59 | $4.28M | $0 | 1 | 2020-03-16 |
| Korro Bio, Inc. (FREQ) Delisted | 10%+ Owner | 956,175 | $14.98 | $14.32M | $0 | 1 | 2019-10-09 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | 10%+ Owner | 214,447 | $329.83 | $70.73M | $480.0K | 1 | 2019-07-05 |
| IDYA | 10%+ Owner | 382,384 | $37.76 | $14.44M | $500.0K | 1 | 2019-05-30 |
| NXTC | 10%+ Owner | 197,993 | $5.00 | $990.1K | $0 | 1 | 2019-05-13 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 149,637 | $33.99 | $5.09M | $1.00M | 1 | 2018-07-23 |
| Evelo Biosciences, Inc. (EVLO) Delisted | 10%+ Owner | 594,443 | $0.00 | $59 | $0 | 1 | 2018-05-21 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | 10%+ Owner | 225,680 | $0.08 | $17.6K | $0 | 1 | 2017-11-20 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-18 | — | Notice (144) | −20,000 | -$2.63M | EDGAR |
| 2025-03-17 | — | Notice (144) | −11,750 | -$1.54M | EDGAR |
| 2024-09-06 | — | Notice (144) | −25,000 | -$1.83M | EDGAR |
| 2024-06-05 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −150,000 | -$636.0K | EDGAR |
| 2024-06-04 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −150,000 | -$630.0K | EDGAR |
| 2023-12-01 | — | Notice (144) | −55,000 | -$3.42M | EDGAR |
| 2023-11-06 | — | Notice (144) | −23,000 | -$1.28M | EDGAR |
| 2023-11-03 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −143,450 | -$329.9K | EDGAR |
| 2023-11-02 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −103,808 | -$240.9K | EDGAR |
| 2023-11-01 | Applied Therapeutics, Inc. (APLT) Delisted | Notice (144) | −172,742 | -$407.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.